Compare MSB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSB | IVVD |
|---|---|---|
| Founded | 1961 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.0M | 437.1M |
| IPO Year | 1995 | 2021 |
| Metric | MSB | IVVD |
|---|---|---|
| Price | $25.70 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 57.5K | ★ 2.4M |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | ★ 391.29 | 79.02 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $98,595,651.00 | $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | $30.10 | ★ N/A |
| Revenue Growth | ★ 331.26 | 110.47 |
| 52 Week Low | $22.55 | $0.49 |
| 52 Week High | $42.38 | $3.07 |
| Indicator | MSB | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 34.88 |
| Support Level | $25.24 | $0.49 |
| Resistance Level | $32.73 | $1.14 |
| Average True Range (ATR) | 1.72 | 0.11 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 20.60 | 13.51 |
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the northeastern end of the Mesabi Iron Range.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.